艾迪注射液联合洛铂腔内注射治疗癌性胸腔积液的临床观察  

Clinical observation on treating cancerous pleural effusion with the Eddy injection plus Lobaplatin

作　　者：钟妙文[1] 唐荣德[1] 叶慧青[1] 黎群足[1] 

机构地区：[1]江门市新会区中医院,广东江门529100

出　　处：《中医临床研究》2015年第29期84-85,共2页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察艾迪注射液联合洛铂腔内注射治疗癌性胸腔积液的临床疗效。方法:38例恶性胸腔积液患者使用单腔中心静脉导管插管闭式引流,当积液基本引流干净时腔内注射艾迪注射液、洛铂、地塞米松和速尿,观察患者治疗后的生活质量、胸腔积液疗效和毒性反应。结果:生活质量显著改善者23例(占60.5%),总有效率为92.1%;胸腔积液完全缓解13例(占34.2%),部分缓解20例(占52.6%),总有效率为86.8%。结论:艾迪注射液联合洛铂腔内注射治疗癌性胸腔积液有较好的疗效,值得在临床上推广应用。Objective： To observe clinical effects of the Eddy injection plus Lobaplatin on cancerous pleural effusion. Methods： 38 patients received the Eddy injection, Lobaplatin, dexamethasone and furosemidum when the effusion was basically cleared. After the treatment, quality of life of the patients, clinical effects of pleural effusion and toxicity responses were observed. Results： Quality of life was significantly improved in 23 cases （accounting for 60.5%）; and the total efficiency was 92.1%. Pleural effusion was completely eased in 13 cases （accounting for 34.2%）, and alleviated partially in 20 cases （accounting for 52.6%）; the total efficiency was 86.8%. Conclusion： The Eddy injection plus Lobaplatin was effective on cancerous pleural effusion, and worthy of promotion.

关 键 词：癌性胸腔积液 艾迪注射液 洛铂 腔内注射 

分 类 号：R561.4[医药卫生—呼吸系统]